United Therapeutics (UTHR) Cash & Current Investments (2009 - 2026)

United Therapeutics (UTHR) has 18 years of Cash & Current Investments data on file, last reported at $2.2 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 35.15% year-over-year to $2.2 billion; the trailing twelve-month figure through Mar 2026 stood at $2.2 billion (down 35.15% YoY), and the FY2025 full-year result was $2.9 billion, down 10.61% from the prior year.
• Cash & Current Investments slipped to $2.2 billion in Q1 2026, from $2.9 billion in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $3.3 billion in Q3 2024 to a low of $2.2 billion in Q1 2026.
• A 5-year average of $2.8 billion and a median of $2.9 billion in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments soared 47.03% in 2022 and tumbled 35.15% in 2026, its largest moves.
• Tracing UTHR's Cash & Current Investments over 5 years: stood at $2.8 billion in 2022, then grew by 5.47% to $3.0 billion in 2023, then advanced by 9.11% to $3.3 billion in 2024, then fell by 10.61% to $2.9 billion in 2025, then slipped by 26.25% to $2.2 billion in 2026.
• Business Quant data shows UTHR's Cash & Current Investments at $2.2 billion in Q1 2026, $2.9 billion in Q4 2025, and $2.8 billion in Q3 2025.